Poolbeg Pharma PLC Announces Significant POLB 001 Patent Granted in USA - Seite 2

Enquiries

Poolbeg Pharma Plc Jeremy Skillington, CEO

Ian O'Connell, CFO

[phone]

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

[phone]

Shore Capital Stockbrokers Ltd (Joint Broker)

David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel Jones (Corporate Broking)

[phone]

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist

[phone]

Optimum Strategic Communications

Nick Bastin, Vici Rabbetts, Elena Bates

 

[phone]

[e-mail]

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.